Metraipolis › archive › dc_8dc742e9725d

MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing — Europe PMC PMID:42159893

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42159893
DOI
10.1007/s11060-[numero omesso]-0
License (as archived)
solo-consultazione
Archived
2026-11-01T13:42:53.007Z
SHA-256 of the archived text
f067a74af6927926eac0f3d10802788cae282c09980bba79f964365e9df9d82a
Stable URL of this page
https://metraipolis.com/documento/dc_8dc742e9725d

How to cite

MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing — Europe PMC PMID:42159893 — Europe PMC (en), https://europepmc.org/article/MED/42159893 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8dc742e9725d (Metraipolis archive dc_8dc742e9725d, sha256 f067a74af6927926eac0f3d10802788cae282c09980bba79f964365e9df9d82a)
BibTeX
@misc{dc8dc742e9725d,
  title = {MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing — Europe PMC PMID:42159893},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42159893},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8dc742e9725d; sha256 f067a74af6927926eac0f3d10802788cae282c09980bba79f964365e9df9d82a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42159893. Agents can read the archived copy with the MCP tool read_document.